Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF | R&D Systems 471-F1-100 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF

catalog :

471-F1-100

quantity :

100 ug

price :

449 USD

more info or order :

R&D Systems product webpage

citations: 24

Reference
Popovic N, Hooker E, Barabino A, Flamier A, Provost F, Buscarlet M, et al. COCO/DAND5 inhibits developmental and pathological ocular angiogenesis. EMBO Mol Med. 2021;13:e12005 pubmed publisher
Di Marco B, Crouch E, Shah B, Duman C, Paredes M, Ruiz de Almodovar C, et al. Reciprocal Interaction between Vascular Filopodia and Neural Stem Cells Shapes Neurogenesis in the Ventral Telencephalon. Cell Rep. 2020;33:108256 pubmed publisher
Mashayekhi V, Xenaki K, van Bergen en Henegouwen P, Oliveira S. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. Cancers (Basel). 2020;12: pubmed publisher
Verma M, Shimizu Motohashi Y, Asakura Y, Ennen J, Bosco J, Zhou Z, et al. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy. PLoS Genet. 2019;15:e1008468 pubmed publisher
Genet G, Boyé K, Mathivet T, Ola R, Zhang F, Dubrac A, et al. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. Nat Commun. 2019;10:2350 pubmed publisher
Dao D, Anez Bustillos L, Jabbouri S, Pan A, Kishikawa H, Mitchell P, et al. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS ONE. 2018;13:e0208579 pubmed publisher
Ikeuchi T, de Vega S, Forcinito P, Doyle A, Amaral J, Rodriguez I, et al. Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity. Sci Rep. 2018;8:17654 pubmed publisher
Atienzar Aroca S, Serrano Heras G, Freire Valls A, Ruiz de Almodovar C, Muriach M, Barcia J, et al. Role of retinal pigment epithelium-derived exosomes and autophagy in new blood vessel formation. J Cell Mol Med. 2018;22:5244-5256 pubmed publisher
Gu J, Yuan S, Sim D, Abe K, Liu P, Rosenbruch M, et al. Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease. Exp Hematol. 2018;60:73-82.e3 pubmed publisher
Liu H, Zhang W, Xu Z, Caldwell R, Caldwell R, Brooks S. Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci. 2013;54:918-31 pubmed publisher
Abramovich D, Irusta G, Bas D, Cataldi N, Parborell F, Tesone M. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology. 2012;153:3446-56 pubmed publisher
Fukushima Y, Okada M, Kataoka H, Hirashima M, Yoshida Y, Mann F, et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J Clin Invest. 2011;121:1974-85 pubmed publisher
Tam Tam K, LaMarca B, Arany M, Cockrell K, Fournier L, Murphy S, et al. Role of reactive oxygen species during hypertension in response to chronic antiangiogenic factor (sFlt-1) excess in pregnant rats. Am J Hypertens. 2011;24:110-3 pubmed publisher
Ponticelli S, Marasco D, Tarallo V, Albuquerque R, Mitola S, Takeda A, et al. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem. 2008;283:34250-9 pubmed publisher
Kubota Y, Hirashima M, Kishi K, Stewart C, Suda T. Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice. J Clin Invest. 2008;118:2393-403 pubmed publisher
Tei K, Matsumoto T, Mifune Y, Ishida K, Sasaki K, Shoji T, et al. Administrations of peripheral blood CD34-positive cells contribute to medial collateral ligament healing via vasculogenesis. Stem Cells. 2008;26:819-30 pubmed publisher
Tsao P, Chan F, Wei S, Hsieh W, Chou H, Su Y, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med. 2007;35:1955-60 pubmed
Ambati B, Nozaki M, Singh N, Takeda A, Jani P, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-7 pubmed
Matsumoto T, Kawamoto A, Kuroda R, Ishikawa M, Mifune Y, Iwasaki H, et al. Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. Am J Pathol. 2006;169:1440-57 pubmed
Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal P, Pesce M, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006;169:1167-82 pubmed
Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A. 2005;102:14016-21 pubmed
Gudehithlu K, Ahmed N, Wu H, Litbarg N, Garber S, Arruda J, et al. Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue. J Lab Clin Med. 2005;145:194-203 pubmed
Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161:1163-77 pubmed
Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-8 pubmed

product information

brand :

R&D Systems

master code :

471-F1

SKU :

471-F1-100

product name :

Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF

description :

The Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

VEGFR1/Flt-1

category :

Proteins and Enzymes

sizes available :

100 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in MOPS, NaCl and CHAPS.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Mouse

observed molecular weight :

150-170 kDa, reducing conditions

theoretical molecular weight :

110 kDa (monomer)

gene symbol :

Flt1

details of functionality :

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. Conn, G. et al . (1990) Proc. Natl. Acad. Sci. USA 87 :1323. The ED50 for this effect is 10-30 ng/mL.

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

accessionNumbers :

P35969

applications :

Bioactivity

extended description :

A New rm VEGF R1 is Available! Enhanced purity; ~1.5x better activity; mouse Fc tag; No His-tag!

source :

NS0-derived Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF

USD :

442

USD 2023 :

449 USD

product details :

A New rm VEGF R1 is Available! Enhanced purity; ~1.5x better activity; mouse Fc tag; No His-tag!

alt names :

EC 2.7.10, EC 2.7.10.1, FLT, FLT1, FLT-1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor), FRT, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, vascular endothelial growth factor receptor 1, Vascular permeability factor receptor, VEGF R1, VEGFR1, VEGFR-1

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage